The tissue-specific receptor sensitisation is likely why BPC-157 does not carry the off-target hormonal effects seen with GH-axis compounds
56.09% of people who had only briefly considered GLP-1s also said they would likely seek treatment
Figure 2: Changes in body weight from baseline to the end of treatment at week 26 associated with the treatment policy estimand, in the randomly assigned treatment groups administered either 0.3 mg of cagrilintide, 0.6 mg of cagrilintide, 1.2 mg of cagrilintide, 2.5 mg of cagrilintide, 4.5 mg of cagrilintide, 3.0 mg of liraglutide, or a placebo
The Phase 3 randomized controlled trial enrolled 2,539 adults with obesity and was published in the New England Journal of Medicine in June 2022 (Jastreboff AM et al, NEJM 2022;387:205-216)
Renal function should be assessed before starting treatment and monitored regularly, particularly during illness or dehydration